H.C. Wainwright reiterates Celcuity stock rating on pricing update
H.C. Wainwright reiterated a Buy rating and $155 price target on Celcuity (NASDAQ:CELC) after its Q2 results and corporate update. Celcuity disclosed wholesale acquisition costs of $10,000 per vial and $30,000 per cycle, targeting gross-to-net around 80%. The company said NCCN named REVTORPYK preferred Category 1 options, with payer coverage over 90% of lives. Q2 loss was $78.9M, or $1.44/share.
How this was made
The 30-second read
Why it matters
The piece is primarily an analyst reiteration (Buy, $155 PT) layered on top of Q2 results and launch-readiness updates, which can influence near-term positioning but does not add a new primary disclosure beyond the referenced guidance and milestones.
Market read
Traders may use the reiterated Buy and PT to gauge sentiment into the late Q3 2026 shipment window, but the article is not a fresh company event.
What to watch
The article highlights payer coverage and expanded access, but does not quantify reimbursement economics beyond gross-to-net guidance, leaving uncertainty around realized net pricing versus modeled assumptions.
Background
Celcuity is preparing for commercial launch of its breast cancer drug REVTORPYK, with payer dossiers and an expanded access program underway.
Ticker impact
H.C. Wainwright reiterated a Buy rating and $155 price target on Celcuity after its Q2 results and corporate update, including wholesale acquisition cost and gross-to-net guidance.
Near-term trading likely follows analyst/PT narrative and any incremental payer or shipping updates into late Q3 2026.
The article’s actionable catalyst is the reiterated Buy with a specific PT, while the company-specific operational milestones (payer dossiers, expanded access shipping, late Q3 shipments) support the bull case; however, the text does not introduce brand-new company disclosures beyond what it references.
Market effects
Reinforces sentiment around oncology drug commercialization readiness and payer formulary progress as key drivers for biotech near-term risk.
No clear regional spillover beyond US-listed biotech sentiment.
Limited global relevance; story is company-specific to Celcuity’s US launch pathway.
Counterpoint
The stock’s large run-up (78% YoY) plus an overvalued fair-value framing suggests upside may be priced in, making the risk-reward sensitive to any launch or reimbursement delays.
Key entities
- public_companyCelcuity Inc
NASDAQ-listed biotech preparing REVTORPYK launch; reported Q2 loss and provided wholesale acquisition cost and gross-to-net guidance.
- drugREVTORPYK
Celcuity breast cancer therapy referenced in NCCN guideline updates and expanded access/shipping progress.
- regulatory_guideline_bodyNational Comprehensive Cancer Network (NCCN)
Named REVTORPYK regimens as preferred Category 1 options for wild-type patients in second-line settings.
